Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/30400
Type
ArticleCopyright
Open access
Embargo date
2019-10-30
Collections
- INI - Artigos de Periódicos [3504]
Metadata
Show full item record
INFLAMMATION AND MICRONUTRIENT BIOMARKERS PREDICT CLINICAL HIV TREATMENT FAILURE AND INCIDENT ACTIVE TB IN HIV-INFECTED ADULTS: A CASE-CONTROL STUDY
Author
Shivakoti, Rupak
Gupte, Nikhil
Tripathy, Srikanth
Poongulali, Selvamuthu
Kanyama, Cecilia
Berendes, Sima
Cardoso, Sandra W.
Santos, Breno R.
La Rosa, Alberto
Mwelase, Noluthando
Pillay, Sandy
Samaneka, Wadzanai
Riviere, Cynthia
Sugandhavesa, Patcharaphan
Bollinger, Robert C.
Balagopal, Ashwin
Semba, Richard D.
Christian, Parul
Campbell, Thomas B.
Gupta, Amita
Gupte, Nikhil
Tripathy, Srikanth
Poongulali, Selvamuthu
Kanyama, Cecilia
Berendes, Sima
Cardoso, Sandra W.
Santos, Breno R.
La Rosa, Alberto
Mwelase, Noluthando
Pillay, Sandy
Samaneka, Wadzanai
Riviere, Cynthia
Sugandhavesa, Patcharaphan
Bollinger, Robert C.
Balagopal, Ashwin
Semba, Richard D.
Christian, Parul
Campbell, Thomas B.
Gupta, Amita
Affilliation
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA./ Columbia University Mailman School of Public Health. Department of Epidemiology. New York, NY, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
National AIDS Research Institute. Pune, India./ National Institute of Research in Tuberculosis. Chennai, India.
YR Gaitonde Center for AIDS Research and Education. Chennai, India.
UNC Lilongwe. Lilongwe, Malawi.
Johns Hopkins University Research Project. Malawi College of Medicine. Blantyre, Malawi./ Liverpool School of Tropical Medicine. Liverpool, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Hospital Nossa Senhora de Conceição. Porto Alegre, RS, Brasil.
Asociacion Civil Impacta Salud y Educacion. Lima, Peru.
University of Witwatersrand. Department of Medicine. Johannesburg, South Africa.
Durban University of Technology. Durban International Clinical Research Site. Durban, South Africa.
University of Zimbabwe. Clinical Research Centre. Harare, Zimbabwe.
Les Centres GHESKIO. Port-Au-Prince, Haiti.
Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA./ Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MD, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
Johns Hopkins University. School of Medicine. Department of Ophthalmology. Baltimore, MD, USA.
Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MD, USA./ Bill and Melinda Gates Foundation. Seattle, USA.
University of Colorado. School of Medicine. Division of Infectious Diseases. Department of Medicine. Aurora, CO, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
National AIDS Research Institute. Pune, India./ National Institute of Research in Tuberculosis. Chennai, India.
YR Gaitonde Center for AIDS Research and Education. Chennai, India.
UNC Lilongwe. Lilongwe, Malawi.
Johns Hopkins University Research Project. Malawi College of Medicine. Blantyre, Malawi./ Liverpool School of Tropical Medicine. Liverpool, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Hospital Nossa Senhora de Conceição. Porto Alegre, RS, Brasil.
Asociacion Civil Impacta Salud y Educacion. Lima, Peru.
University of Witwatersrand. Department of Medicine. Johannesburg, South Africa.
Durban University of Technology. Durban International Clinical Research Site. Durban, South Africa.
University of Zimbabwe. Clinical Research Centre. Harare, Zimbabwe.
Les Centres GHESKIO. Port-Au-Prince, Haiti.
Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA./ Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MD, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
Johns Hopkins University. School of Medicine. Department of Ophthalmology. Baltimore, MD, USA.
Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MD, USA./ Bill and Melinda Gates Foundation. Seattle, USA.
University of Colorado. School of Medicine. Division of Infectious Diseases. Department of Medicine. Aurora, CO, USA.
Johns Hopkins University. School of Medicine. Department of Medicine. Baltimore, MD, USA.
Abstract
Background: Various individual biomarkers of inflammation and micronutrient status, often correlated with each other, are associated with adverse treatment outcomes in human immunodeficiency virus (HIV)-infected adults. The objective of this study was to conduct exploratory factor analysis (EFA) on multiple inflammation and micronutrient biomarkers to identify biomarker groupings (factors) and determine their association with HIV clinical treatment failure (CTF) and incident active tuberculosis (TB). Methods: Within a multicountry randomized trial of antiretroviral therapy (ART) efficacy (PEARLS) among HIV-infected
adults, we nested a case-control study (n = 290; 124 cases, 166 controls) to identify underlying factors, based on EFA of 23 baseline (pre-ART) biomarkers of inflammation and micronutrient status. The EFA biomarker groupings results were used in Cox proportional hazards models to study the association with CTF (primary analysis where cases were incident
World Health Organization stage 3, 4 or death by 96 weeks of ART) or incident active TB (secondary analysis). Results: In the primary analysis, based on eigenvalues> 1 in the EFA, three factors were extracted: (1) carotenoids), (2) other nutrients, and (3) inflammation. In multivariable-adjusted models, there was an increased hazard of CTF (adjusted hazard ratio (aHR) 1.47, 95% confidence interval (CI)1.17–1.84) per unit increase of inflammation factor score. In the secondary incident active TB case-control analysis, higher scores of the high carotenoids and low interleukin-18 factor was protective against incident active TB (aHR 0.48, 95% CI 0.26–0.87). Conclusion: Factors identified through EFA were associated with adverse outcomes in HIV-infected individuals. Strategies focused on reducing adverse HIV outcomes through therapeutic interventions that target the underlying factor (e.g., inflammation) rather than focusing on an individual observed biomarker might be more effective and warrant further investigation.
Share